Fosmanogepix

Fosmanogepix is an antifungal drug that is currently under development. It is a first-in-class agent that works by inhibiting the enzyme Gwt1, which is essential for the growth and survival of fungi. Fosmanogepix has shown promise in treating a wide range of fungal infections, including those caused by Candida, Aspergillus, and rare molds.

Mechanism of Action

Fosmanogepix works by inhibiting the enzyme Gwt1. This enzyme is involved in the synthesis of glycosylphosphatidylinositol (GPI), which is a component of the fungal cell wall. By inhibiting Gwt1, fosmanogepix disrupts the integrity of the fungal cell wall, leading to cell death.

Clinical Trials

Fosmanogepix is currently in Phase 2 clinical trials for the treatment of invasive fungal infections. Preliminary results have shown that it is well-tolerated and effective against a broad range of fungal pathogens, including drug-resistant strains.

Potential Applications

If approved, fosmanogepix could be used to treat a variety of fungal infections, including invasive candidiasis, aspergillosis, and rare mold infections. It could also be a valuable treatment option for patients with immunocompromised conditions, who are at increased risk of developing serious fungal infections.

See Also

• Antifungal drug
• Clinical trial
• Gwt1
• Glycosylphosphatidylinositol
• Invasive candidiasis
• Aspergillosis

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian